Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trilaciclib with Chemotherapy and Tislelizumab in Advanced Squamous NSCLC
NCT05900921Phase 2Not yet recruiting
- Sponsor
- Sichuan University
- Start
- Jul 2023
- Primary completion
- Oct 2024
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of trilaciclib in squamous cell carcinoma of the lung (SCCL) (2 arms), sponsored by Sichuan University. Primary endpoint: Incidence of Grade >=3 Neutrophil Count Decreased. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
trilaciclib
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT05900921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05900921.